|
CA2273083C
(en)
|
1996-12-03 |
2012-09-18 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US7407975B2
(en)
|
1997-08-09 |
2008-08-05 |
Bayer Schering Pharma Ag |
Epothilone derivatives, method for producing same and their pharmaceutical use
|
|
FR2775187B1
(en)
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
|
|
NZ511722A
(en)
|
1998-11-20 |
2004-05-28 |
Kosan Biosciences Inc |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
|
AU4101800A
(en)
*
|
1999-02-11 |
2000-08-29 |
Schering Aktiengesellschaft |
Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
|
|
ES2391550T3
(en)
|
1999-04-15 |
2012-11-27 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
AU772750C
(en)
|
1999-04-30 |
2005-02-24 |
Schering Aktiengesellschaft |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
|
US20020045609A1
(en)
*
|
2000-05-26 |
2002-04-18 |
Gary Ashley |
Epothilone derivatives and methods for making and using the same
|
|
IL155306A0
(en)
|
2000-10-13 |
2003-11-23 |
Univ Mississippi |
Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
|
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
|
DK1483251T3
(en)
|
2002-03-12 |
2010-04-12 |
Bristol Myers Squibb Co |
C3-cyano-epothilone derivatives
|
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
EP1567487A4
(en)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
|
WO2008070672A2
(en)
|
2006-12-04 |
2008-06-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to treat cancer with cupredoxins and cpg rich dna
|
|
CN101668536A
(en)
|
2007-02-08 |
2010-03-10 |
伊利诺斯大学理事会 |
Compositions and methods for preventing cancer with cupredoxins
|
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
|
DE102007059752A1
(en)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Functionalized solid polymer nanoparticles containing epothilones
|
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
|
EP2571525A4
(en)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Compositions and methods for treatment of autoimmune and other diseases
|
|
EP2665493B1
(en)
|
2011-01-20 |
2018-03-21 |
Board Of Regents, The University Of Texas System |
Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
|
|
CN102863474A
(en)
|
2011-07-09 |
2013-01-09 |
陈小平 |
Platinum compounds for treating cell proliferative diseases and preparation method and application thereof
|
|
CN102993239A
(en)
|
2011-09-19 |
2013-03-27 |
陈小平 |
Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino
|
|
WO2013092998A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
US9725477B2
(en)
|
2012-11-17 |
2017-08-08 |
Beijing Fswelcome Technology Development Co., Ltd |
Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
WO2014202775A1
(en)
|
2013-06-21 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|